Home \ Antibodies \ TNF-RI, Mouse, mAb 55R-170, FITC
Placeholder
Catalog # HM1097F

TNF-RI, Mouse, mAb 55R-170, FITC

Please choose the quantity of items you wish to add to your cart…
Find distributor

The monoclonal antibody 55R-170 recognizes the extracellular part of mouse Tumor Necrosis Factor Receptor superfamily member 1A (TNF-RI), also known as CD120a or p55. TNF-RI belongs to the large TNF receptor family, among which TNF-RII (TNF-R p75-80), lymphotoxin-beta receptor (LTbetaR) and the Herpes virus entry mediator (HVEM). Ligands for these receptors belong to the Tumor Necrosis Factor (TNF) superfamily of cytokines, which activate signaling pathways for cell survival, death, and differentiation that orchestrate the development, organization and homeostasis of lymphoid, mammary, neuronal and ectodermal tissues.
TNF-RI contains a characteristic structural cassette termed death domain in its sequence that is conserved within a distinct subset of other TNF-R family members, such as CD95, DR3, DR4, and DR5. This death domain, was characterized as being essential for induction of apoptosis in vitro and has been structurally conserved within these TNF-R superfamily members. Deletion of the death domain of the TNF-RI results in a non-functional receptor, indicating that the death domain is required for the signal transduction of the physiological functions of TNF-RI in vivo.
TNF-RI is a 55 kD type I transmembrane protein and is expressed on a variety of cell types at low levels. It is considered to play a prominent role in cell stimulation by TNF-alpha. Induction of cytotoxicity and other functions are mediated largely via TNF-RI. TNF-RI is present as soluble form in body fluids (for instance plasma and CSF). This extracellular TNF-RI is generated by two mechanisms, namely proteolytic cleavage of TNF-RI ectodomains and release of full-length TNF-RI in the membranes of exosome-like vesicles. TNF-RI and TNF-RII both interact with the homomeric forms of LTbeta or TNF. However, TNF-RI functions as the high affinity receptor for soluble TNF (sTNF). TNF-RI has been shown to be involved in a wide variety of inflammatory diseases, among which neurodegenerative diseases (Parkinson’s and Alzheimer’s disease), multiple sclerosis, asthma, atherosclerosis, rheumatology.
The monoclonal antibody 55R-170 also recognizes the soluble receptor.

Application
Flow cytometry, Functional studies, Immuno assays, Immuno precipitation

Application Notes
FS: Antibody 55R-170 is an antagonistic antibody useful for blocking of TNR-RI.
IA: Antibody 55R-170 can be used as a detection antibody.

Use
Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

Product type
Monoclonal antibodies
Amount
100 µg, 20 µg
Formulation
0.2 ml (100 μg/ml) 0.2 μm protein G purified FITC conjugated antibody solution in PBS, containing 1% bovine serum albumin and 0.02% sodium azide.
Conjugate
FITC
Immunogen
Purified soluble extracellular domain of mouse TNF-RI (Ref.1).
Isotype
Armenian hamster IgG
Species
Human
Cross reactivity
Rat – No
Alias
Tumor necrosis factor receptor superfamily member 1A, Tumor necrosis factor receptor 1, Tumor necrosis factor receptor type I, TNFR-I, p55, p60, CD120a<br> - Gene name: Tnfrsf1a, Tnfr-1, Tnfr1
Storage and stability
Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year.
Precautions
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Disease
Autoimmunity, Gastroenterology

Calculate your ELISA data easily

With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.

Latest Hycult Biotech news

  • New Human Complement Pathway Assays
    We are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
  • Navigating the pitfalls in complement analysis
    Our colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
  • NEW Human C3d ELISA
    We are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA
Contact us